Follow
Alexander T. Baker
Alexander T. Baker
Accession Therapeutics/Cardiff University
Verified email at accessiontherapeutics.com - Homepage
Title
Cited by
Cited by
Year
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome
AT Baker, RJ Boyd, D Sarkar, A Teijeira-Crespo, CK Chan, E Bates, ...
Science Advances 7 (49), eabl8213, 2021
1382021
Designer oncolytic adenovirus: coming of age
AT Baker, C Aguirre-Hernández, G Halldén, AL Parker
Cancers 10 (6), 201, 2018
952018
Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor
AT Baker, RM Mundy, JA Davies, PJ Rizkallah, AL Parker
Science advances 5 (9), eaax3567, 2019
77*2019
Oncolytic virotherapy: Challenges and solutions
NH Goradel, AT Baker, A Arashkia, N Ebrahimi, S Ghorghanlu, ...
Current problems in cancer 45 (1), 100639, 2021
742021
Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions
AT Baker, A Greenshields-Watson, L Coughlan, JA Davies, ...
Nature communications 10 (1), 741, 2019
542019
The fish pathogen Yersinia ruckeri produces holomycin and uses an RNA methyltransferase for self-resistance
Z Qin, AT Baker, A Raab, S Huang, T Wang, Y Yu, M Jaspars, ...
Journal of Biological Chemistry 288 (21), 14688-14697, 2013
532013
Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies
H Uusi-Kerttula, JA Davies, JM Thompson, P Wongthida, L Evgin, ...
Clinical Cancer Research 24 (17), 4215-4224, 2018
422018
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination
A Buoninfante, A Andeweg, AT Baker, M Borad, N Crawford, JM Dogné, ...
npj Vaccines 7 (1), 141, 2022
232022
To clot or not to clot? Ad is the question—Insights on mechanisms related to vaccine‐induced thrombotic thrombocytopenia
M Othman, AT Baker, E Gupalo, A Elsebaie, CM Bliss, MT Rondina, ...
Journal of Thrombosis and Haemostasis 19 (11), 2845-2856, 2021
232021
Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy
PLS Uson Junior, U Majeed, J Yin, G Botrus, MB Sonbol, DH Ahn, ...
JCO Precision Oncology 6 (1), e2100274, 2022
112022
The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism
AT Baker, JA Davies, EA Bates, E Moses, RM Mundy, G Marlow, DK Cole, ...
Journal of Virology 95 (4), 10.1128/jvi. 01849-20, 2021
112021
Oncolytic virus with attributes of vesicular stomatitis virus and measles virus in hepatobiliary and pancreatic cancers
BM Nagalo, CA Breton, Y Zhou, M Arora, JM Bogenberger, O Barro, ...
Molecular Therapy-Oncolytics 18, 546-555, 2020
112020
Exploring cryo-electron microscopy with molecular dynamics
JW Vant, D Sarkar, J Nguyen, AT Baker, JV Vermaas, A Singharoy
Biochemical Society Transactions 50 (1), 569-581, 2022
102022
Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications
SL Hulin-Curtis, JA Davies, D Nestić, EA Bates, AT Baker, TG Cunliffe, ...
Cancer gene therapy 27 (10), 785-798, 2020
92020
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers
M Arora, JM Bogenberger, AM Abdelrahman, J Yonkus, R Alva‐Ruiz, ...
Hepatology 75 (1), 43-58, 2022
62022
In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications
EA Bates, JR Counsell, S Alizert, AT Baker, N Suff, A Boyle, AC Bradshaw, ...
Viruses 13 (8), 1483, 2021
62021
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
BM Nagalo, Y Zhou, EJ Loeuillard, C Dumbauld, O Barro, NM Elliott, ...
Hepatology 77 (6), 1943-1957, 2023
52023
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
PLS Uson Junior, TT DeLeon, JM Bogenberger, RK Pai, HE Kosiorek, ...
Digestive diseases and sciences, 1-9, 2022
52022
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10
EA Bates, JA Davies, J Váňová, D Nestić, VS Meniel, S Koushyar, ...
Molecular Therapy-Oncolytics 25, 43-56, 2022
52022
Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma
CR Watters, O Barro, NM Elliott, Y Zhou, M Gabere, E Raupach, AT Baker, ...
Molecular Therapy-Oncolytics 29, 4-14, 2023
12023
The system can't perform the operation now. Try again later.
Articles 1–20